Form 4: Enliven CSO Sells 4,000 Shares Under 10b5-1 Plan

Enliven Therapeutics' Chief Scientific Officer, Joseph P. Lyssikatos, sold 4,000 shares of common stock for approximately $20.25 per share pursuant to a pre-arranged Rule 10b5-1 trading plan.

Summary

• Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, Inc. (ELVN), reported a sale of common stock.
• The transaction involved 4,000 shares of common stock.
• The shares were sold on September 26, 2025, at a weighted average price of $20.2513 per share.
• The total value of the shares sold is approximately $81,005.20.
• The sale was executed under a Rule 10b5-1 trading plan adopted on November 15, 2024.
• Following this transaction, Mr. Lyssikatos beneficially owns 927,688 shares indirectly through The Lyssikatos Revocable Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it's an insider sale, which can sometimes be viewed negatively, the fact that it's executed under a pre-arranged 10b5-1 plan mitigates concerns that it's based on new, adverse information. It's likely for personal financial planning or diversification.

Positives

• An insider selling shares under a pre-arranged Rule 10b5-1 plan indicates the transaction was scheduled in advance and not necessarily based on new, negative material non-public information.

Negatives

• Insider selling, even if planned, can sometimes be perceived by the market as a lack of confidence or a move to diversify holdings, potentially putting downward pressure on the stock.

Risks

• No specific risks beyond the general market perception of insider selling, which could lead to short-term negative sentiment.

Future Outlook

NA

Management Comments

• The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

Industry Context

This Form 4 filing is specific to an individual insider transaction at Enliven Therapeutics and does not directly relate to broader industry trends or competitor activities. Insider transactions are common across all industries.

Related Party Transactions

• The 927,688 shares beneficially owned following the transaction are held indirectly by The Lyssikatos Revocable Trust 12/15/2011, for which the Reporting Person serves as trustee.

Stakeholder Impact

• Shareholders may interpret the insider sale as a signal, though the presence of a 10b5-1 plan suggests it is a pre-scheduled event rather than a reaction to new company developments.

Key Dates

Recommendation

A single insider sale, particularly one executed under a Rule 10b5-1 trading plan, typically does not provide sufficient information to warrant a strong 'buy' or 'sell' recommendation. Such sales are often for personal financial planning, diversification, or liquidity purposes and are pre-scheduled, reducing the likelihood that they are based on new, material non-public information. Investors should consider this transaction in the broader context of the company's financial performance, strategic outlook, and overall market conditions.

Keywords

Enliven Therapeutics, ELVN, Joseph P Lyssikatos, Chief Scientific Officer, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Beneficial Ownership